We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Acute COVID-19 Infections Are Characterized by Elevated Blood Levels of IL-26

By LabMedica International staff writers
Posted on 22 Nov 2022
Print article
Image: Mild versus severe immune response during COVID-19 infection (Photo courtesy of Wikimedia Commons)
Image: Mild versus severe immune response during COVID-19 infection (Photo courtesy of Wikimedia Commons)

The most severe form of COVID-19 infection is characterized by elevated levels of the cytokine interleukin-26 (IL-26) in the blood.

IL-26 is an inflammatory mediator and a driver of chronic inflammation that may be categorized as a kinocidin due to its ability to act as a carrier of extracellular DNA and as an antimicrobial molecule through its capacity to form pores in bacterial membranes. IL-26 is released by several immune and structural cells following stimulation of toll-like receptors (TLRs), whereupon it can directly inhibit viral replication and enhance neutrophil chemotaxis. Given these unique properties, IL-26 has emerged as an intriguing mediator of host defense in the lungs. However, the role of IL-26 in COVID-19 has not been thoroughly investigated.

To correct this lapse, investigators at the Karolinska Institutet (Stockholm, Sweden) worked with 49 patients who had been hospitalized with SARS-CoV-2-infection, 44 of whom had severe symptoms and needed oxygen therapy. A control group of 27 healthy individuals was also recruited. The investigators measured levels of IL-26 protein and other inflammatory compounds blood samples obtained from the patients and control subjects.  

Results revealed that IL-26 was markedly increased in blood samples from the acutely ill patients, and that the concentration of IL-26 correlated with those of the neutrophil-mobilizing cytokines IL-8 and TNFalpha, respectively. Moreover, the increase in blood IL-26 correlated with enhanced surface expression of CD47 on blood neutrophils isolated from patients with acute COVID-19. In addition, the results showed that the blood concentration of IL-26 correlated with that of increased lactate dehydrogenase, an established marker of tissue damage, and decreased mean corpuscular hemoglobin (MCH), a previously verified hematological aberration in COVID-19, both of which are associated with severe disease.

Taken together, the findings indicated that increased systemic IL-26 associated with markers of hyperinflammation and tissue damage in patients with acute COVID-19, suggesting that it may be a potential target for diagnosis, monitoring, and therapy in this disease.

“We already know that IL-26 is engaged in mobilizing immune cells that combat bacterial infections in the lungs and also in chronic respiratory disease in humans,” said senior author Dr. Anders Lindén, professor of environmental medicine at the Karolinska Institutet. “What is more, IL-26 has antiviral and antibacterial effects. Our discovery gives us a potential biomarker for severe COVID-19, but given the antiviral effects of IL-26, we may also have identified a new therapeutic target.”

The association between elevated IL-26 and acute COVID-19 was discussed in the November 17, 2022, online edition of the journal Frontiers in Immunology.

Related Links:
Karolinska Institutet

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.